Lilly's ramucirumab meets Phase III colorectal endpoint

Eli Lilly and Co. (NYSE:LLY) said ramucirumab plus chemotherapy increased overall survival, the primary endpoint, in a Phase III trial as second-line therapy for metastatic colorectal cancer (mCRC). The company declined to provide specific data until it presents them at an unspecified scientific meeting in 2015.

The human IgG1 mAb VEGFR-2 antagonist also increased progression-free survival, a secondary endpoint. ...